Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | ULK1 | O75385 | 6/20 | 0.40 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30822853 | 0.88 | PRKCI (0.46) | PRKCIAXLJAK1JAK2AURKA | |
| SCHEMBL22792992 | 0.88 | PRKCI (0.46) | PRKCIAXLJAK1JAK2AURKA | |
| SCHEMBL18012903 | 0.80 | PRKCI (0.49) | PRKCIAXLULK1JAK1JAK2 | |
| SCHEMBL16154738 | 0.80 | PRKCI (0.45) | PRKCIAXLJAK1JAK2AURKA | |
| SCHEMBL18924319 | 0.80 | PRKCI (0.45) | PRKCIAXLJAK1JAK2AURKA | |
| SCHEMBL19104289 | 0.78 | PRKCI (0.59) | PRKCIAXLJAK1JAK2AURKA | |
| SCHEMBL1467223 | 0.77 | PRKCI (0.57) | PRKCIAXLULK1JAK1JAK2 | |
| SCHEMBL21855819 | 0.77 | PRKCI (0.41) | PRKCIAXLULK1JAK1JAK2 | |
| SCHEMBL30543159 | 0.77 | PRKCI (0.57) | PRKCIAXLULK1JAK1JAK2 | |
| SCHEMBL21893423 | 0.77 | ULK1 (0.47) | PRKCIAXLULK1JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PRKCI 1350/4885AXL 3955/4885ULK1 1241/4885 |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK2A1 | PRKCI 42/4885AXL 2738/4885ULK1 345/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PRKCI 1350/4885AXL 3955/4885ULK1 1241/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | PRKCI 1350/4885AXL 3955/4885ULK1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.